相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma
Zhi-Qiang Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
Johann von Felden et al.
ONCOGENE (2021)
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Han Si et al.
CLINICAL CANCER RESEARCH (2021)
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
Jean-Charles Nault et al.
HEPATOLOGY (2020)
miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation
Amani Ghousein et al.
LIVER INTERNATIONAL (2020)
Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma
Jialei Weng et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2020)
Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review
Vincent L. Chen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy
Takeshi Yamada et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
Marco Russano et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Applications of cell-free circulating tumor DNA detection in EGFR mutant lung cancer
Ajaz Bulbul et al.
JOURNAL OF THORACIC DISEASE (2020)
RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients
Ninzi Tian et al.
OPEN MEDICINE (2020)
Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer
Hao Liao et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma
Jian Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
Susanne Klein-Scory et al.
FRONTIERS IN ONCOLOGY (2020)
New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma
Ting Wang et al.
FRONTIERS IN ONCOLOGY (2020)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al.
NATURE MEDICINE (2020)
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Qu Zhang et al.
CANCER DISCOVERY (2020)
The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma
Guo Long et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2020)
ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
Marcela Carausu et al.
JOURNAL OF BREAST CANCER (2020)
The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids
Junqiang Wei et al.
JOURNAL OF CANCER (2020)
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
Chung Ryul Oh et al.
BMC CANCER (2019)
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma
Jessica Howell et al.
EUROPEAN JOURNAL OF CANCER (2019)
Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
Jiabin Cai et al.
GUT (2019)
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer
Erik J. van Helden et al.
MOLECULAR ONCOLOGY (2019)
Somatic mutations and clonal dynamics in healthy and cirrhotic human liver
Simon F. Brunner et al.
NATURE (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib
Kenichiro Kodama et al.
ONCOLOGY (2019)
Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients
Masami Yamauchi et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Oliver A. Zill et al.
CLINICAL CANCER RESEARCH (2018)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics
Sadakatsu Ikeda et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
Sadakatsu Ikeda et al.
ONCOLOGIST (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer
Elodie Henriet et al.
CELL ADHESION & MIGRATION (2018)
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
David Tamborero et al.
GENOME MEDICINE (2018)
Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2018)
A novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model
Tracy Nance et al.
CANCER RESEARCH (2018)
Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab
Rajiv Raja et al.
CLINICAL CANCER RESEARCH (2018)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
Jianhua Liu et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2017)
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
Malachi Griffith et al.
NATURE GENETICS (2017)
Tumor Evolution as a Therapeutic Target
Nabil Amirouchene-Angelozzi et al.
CANCER DISCOVERY (2017)
InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines
Quan Li et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Kornelius Schulze et al.
JOURNAL OF HEPATOLOGY (2016)
ATM Mutations in Cancer: Therapeutic Implications
Michael Choi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
Chiara Ambrogio et al.
NATURE MEDICINE (2016)
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis
Ines Jeric et al.
NATURE COMMUNICATIONS (2016)
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity
Ao Huang et al.
JOURNAL OF CANCER (2016)
KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
Chiara Ambrogio et al.
ESMO OPEN (2016)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Mohsen Naghavi et al.
LANCET (2015)
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al.
NATURE GENETICS (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy
Atsushi Ono et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2015)
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Yasushi Totoki et al.
NATURE GENETICS (2014)
ClinVar: public archive of relationships among sequence variation and human phenotype
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2014)
Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing
K. C. Allen Chan et al.
CLINICAL CHEMISTRY (2013)
Identification of Driver Genes in Hepatocellular Carcinoma by Exome Sequencing
Sean P. Cleary et al.
HEPATOLOGY (2013)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
Jean Charles Nault et al.
NATURE COMMUNICATIONS (2013)
Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling
Shun Fujimaki et al.
CANCER LETTERS (2012)
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Ke Lin et al.
CLINICAL CANCER RESEARCH (2012)
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators
Akihiro Fujimoto et al.
NATURE GENETICS (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ras Stabilization Through Aberrant Activation of Wnt/β-Catenin Signaling Promotes Intestinal Tumorigenesis
Woo-Jeong Jeong et al.
SCIENCE SIGNALING (2012)
Loss of expression of ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN
Andrew D. Beggs et al.
ONCOTARGET (2012)
Tumour evolution inferred by single-cell sequencing
Nicholas Navin et al.
NATURE (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-κB pathway activation
Sanjeev Das et al.
CANCER RESEARCH (2006)
Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C -: A systematic review and critical analysis
S Gupta et al.
ANNALS OF INTERNAL MEDICINE (2003)
p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop
PP Ongusaha et al.
EMBO JOURNAL (2003)
分享论文
